EMPEROR reduced - empagliflozin u nemocných se srdečním selháním se sníženou ejekční frakcí
| Title in English | EMPEROR reduced - empagliflozin in patients with heart failure and reduced ejection fraction |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.casopisvnitrnilekarstvi.cz/artkey/vnl-202101-0006_emperor-reduced-empagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction.php |
| Doi | http://dx.doi.org/10.36290/vnl.2021.006 |
| Keywords | SGLT2 inhibitors; empagliflozin; heart failure |
| Description | Type 2 diabetes mellitus (T2DM) is common in patients with chronic heart failure and is associated with high morbidity and mortality. Significant advances have recently occured in the treatment of diabetes mellitus type 2 (T2DM) and cardiovascular diseases. Several new glucose lowering drugs have shown either neutral or positive cardiovascular effect especially on hospitalisations, but also on mortality. Some of these drugs have safety characteristics with strong practical implication in heart failure, for example sodium-glucose co-transporters type 2 inhibitors (SGLT-2). Position paper of the European Society of Cardiology/Heart Failure Association was published in October 2019 and in June 2020. The results of EMPEROR reduced study were presented on European congress in september 2020. In this phase III, placebo-controlled trial, 3730 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less were randomly assigned to receive either empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. Over a median of 16 months, the primary outcome (cardiovascular mortality and hospitalisation for heart failure) occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients with and without diabetes and in those taking and not taking sacubitril/valsartan. The rate of decline in eGFR was slower in the empagliflozin group than in the placebo group (-0.2 ml/min/1.73m2/year vs -2.3 ml/min/1.73m2/year), P< 0.001, |